Rani Therapeutics
RANI
37 hedge funds and large institutions have $10.7M invested in Rani Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
76% more call options, than puts
Call options by funds: $123K | Put options by funds: $70K
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
9% more funds holding
Funds holding: 34 → 37 (+3)
0.53% more ownership
Funds ownership: 12.73% → 13.26% (+0.53%)
2% less capital invested
Capital invested by funds: $10.9M → $10.7M (-$199K)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$283K |
| 2 |
Renaissance Technologies
New York
|
+$91.5K |
| 3 |
HF
HRT Financial
New York
|
+$77.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASGS
Alpha Square Group S
New York
|
-$87.8K |
| 2 |
Morgan Stanley
New York
|
-$27.3K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$26.7K |
| 4 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
-$9.63K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
26
Islay Capital Management
Lubbock,
Texas
| $29.9K | – | – | – |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $28.4K | – | – | – |
|
|
AF
28
Allworth Financial
Folsom,
California
| $9.7K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $9.33K | +$10.3K | +3,000 | New |
|
|
30
Morgan Stanley
New York
| $7.62K | -$27.3K | -7,951 | -76% |
|
|
31
Simplex Trading
Chicago,
Illinois
| $4K | -$26.7K | -7,772 | -85% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $3.85K | -$3.68K | -1,069 | -46% |
|
33
RhumbLine Advisers
Boston,
Massachusetts
| $970 | – | – | – |
|
34
Wells Fargo
San Francisco,
California
| $320 | +$3 | +1 | +1% |
|
35
Barclays
London,
United Kingdom
| $121 | +$134 | +39 | New |
|
36
Qube Research & Technologies (QRT)
London,
United Kingdom
| $9 | – | – | – |
|
|
IWP
37
IAG Wealth Partners
Waukesha,
Wisconsin
| – | -$3.34K | -1,005 | Closed |
|
RANI Hedge Fund Activity: Q1 2024 in Review
37 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q1 2024, worth a combined $10.7M — down 1.8% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RANI positions and 1 closed out — a net gain of 3 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Stifel Financial, adding an estimated $283K. The largest seller was Alpha Square Group S, cutting an estimated $87.8K.
- 37 institutional investors held Rani Therapeutics (RANI) as of Q1 2024, up from 34 in Q4 2023.
- Funds reported $10.7M of Rani Therapeutics stock for Q1 2024, down 1.8% quarter-over-quarter.
- 4 funds opened new Rani Therapeutics positions in Q1 2024 and 1 closed out, a net change of +3 holders.
- The largest Rani Therapeutics buyer in Q1 2024 was Stifel Financial, an estimated $283K added.
- The largest Rani Therapeutics seller in Q1 2024 was Alpha Square Group S, an estimated $87.8K sold.
Based on aggregated 13F filings for Q1 2024.